Hematologic improvement in response to anti-tumor necrosis factor (TNF) therapy with Remicade® in patients with myelodysplastic syndromes (MDS).

被引：0
|
作者：
Raza, A [1 ]
Lisak, LA [1 ]
Tahir, S [1 ]
Billmeier, JM [1 ]
Willmann, HS [1 ]
Bellak, DJ [1 ]
Alvi, MI [1 ]
Gezer, S [1 ]
Venugopal, P [1 ]
机构：
[1] Rush Univ, Rush Canc Inst, MDS Ctr, Chicago, IL 60612 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3141
引用
收藏
页码：795A / 795A
页数：1
相关论文
共 50 条
  • [1] Effect of cA2 anti-tumor necrosis factor-α antibody therapy on hematopoiesis of patients with myelodysplastic syndromes
    Boula, Anna
    Voulgarelis, Michael
    Giannouli, Stavroula
    Katrinakis, George
    Psyllaki, Maria
    Pontikoglou, Charalambos
    Markidou, Fotini
    Eliopoulos, George D.
    Papadaki, Helen A.
    CLINICAL CANCER RESEARCH, 2006, 12 (10) : 3099 - 3108
  • [2] Effect of proteasome inhibition by bortezomib on tumor necrosis factor alpha (TNF-α) and apoptosis in patients with Myelodysplastic syndromes (MDS).
    Shetty, V
    Verspoor, F
    Nguyen, H
    Gallegos, A
    Mundle, S
    Chaudhry, N
    Imran, M
    Mahmud, G
    Mumtaz, M
    Candoni, A
    Yousffi, M
    Alvi, S
    Reddy, PL
    Galili, N
    Gezer, S
    Venugopal, P
    Raza, A
    BLOOD, 2003, 102 (11) : 422A - 422A
  • [3] Anti-cytokine therapy produces response in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Gezer, S
    Gregory, SA
    Venugopal, P
    Kaizer, H
    Dong, LM
    Span, L
    Hines, C
    Thomas, R
    Alvi, S
    Mundle, SD
    Shetty, V
    Borek, R
    Loew, J
    Reza, S
    Robin, EL
    Rifkin, SD
    Alston, D
    Hernandez, BM
    Shah, R
    Hsu, WT
    Dar, S
    Preisler, HD
    BLOOD, 1996, 88 (10) : 2310 - 2310
  • [4] Biologic and clinical response to recombinant human soluble tumor necrosis factor receptor (enbrel) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Allampallam, K
    Shetty, V
    Mundle, S
    Borok, R
    Lisak, L
    Andrews, C
    Ekbal, M
    Mazzoran, L
    Zorat, F
    Henderson, B
    Dangerfield, B
    Ansaarie, I
    Hussaini, S
    Broady-Robinson, L
    Venugopal, P
    BLOOD, 1999, 94 (10) : 171B - 171B
  • [5] Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide
    Raza, A
    Lisak, L
    Little, L
    Andrews, C
    Meyer, P
    Ekbal, M
    Venugopal, P
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 103 - 104
  • [6] Leukocytoclastic vasculitis associated with anti-tumor necrosis factor (TNF) therapy.
    Mohan, N
    Edwards, ET
    Capps, TR
    Slifman, NR
    Braun, MM
    Lee, JH
    Siegel, JN
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S165 - S165
  • [7] Lenalidomide-induced cytopenias: Relationship to hematologic improvement in patients with myelodysplastic syndromes (MDS)
    Sekeres, Mikkael A.
    Maciejewski, Jwoslaw P.
    Giagounidis, Aristoteles
    Wride, Kenton
    Knight, Robert D.
    Raza, Azra
    List, Alan F.
    BLOOD, 2007, 110 (11) : 252A - 252A
  • [8] Neutropenia in Patients Receiving Anti-Tumor Necrosis Factor Therapy
    Hastings, Richard
    Ding, Tina
    Butt, Sayqa
    Gadsby, Kate
    Zhang, Weiya
    Moots, Robert J.
    Deighton, Chris
    ARTHRITIS CARE & RESEARCH, 2010, 62 (06) : 764 - 769
  • [9] Effect of pentoxifylline and ciprofloxacin (Cipro) on the levels of tumor necrosis factor alpha (TNF-alpha) in myelodysplastic syndromes (MDS).
    Shetty, V
    Gregory, S
    Gezer, S
    Venugopal, P
    Hines, C
    Mundle, S
    Alvi, S
    Borok, R
    Robin, E
    Rifkin, S
    Klein, M
    Alston, D
    Hernandez, B
    Hsu, WT
    Raza, A
    BLOOD, 1995, 86 (10) : 3193 - 3193
  • [10] Infections and anti-tumor necrosis factor α therapy
    Ellerin, T
    Rubin, RH
    Weinblatt, ME
    ARTHRITIS AND RHEUMATISM, 2003, 48 (11): : 3013 - 3022
12345